AmpliPhi raises $7m in placement
Bacteriophage-based treatment company AmpliPhi Biosciences has completed a $7 million private placement to fund its development activities.
The financing round was led by established life sciences investors RA Capital Management and Third Security. BioScience Managers also participated.
“We are very pleased to have the support of these outstanding life science investors,” AmpliPhi CEO Philip J Young said.
As part of its investment, Third Security will appoint managing director Julian P Kirk to the AmpliPhi board. Existing AmpliPhi board members Dr Caroline Williams and Tony Gellert have meanwhile stepped down.
US-based AmpliPhi last year merged with Australia’s Special Phage Services. Gellert had joined the board as a result of this merger.
The combined company is focused on developing antibacterial treatments for antibiotic-resistant bacterial infections. Its lead program centres on treatments for chronic and acute lung infections.
Damaged RNA, not DNA, revealed as main cause of acute sunburn
Sunburn has traditionally been attributed to UV-induced DNA damage, but it turns out that this is...
Multi-ethnic studies identify new genes for depression
Two international studies have revealed hundreds of previously unknown genetic links to...
Oxygen deprivation may contribute to male infertility
Medical conditions that deprive the testes of oxygen, such as sleep apnoea, may be contributing...
